For Merck & Co. the bad news doesn’t seem to end. On the heels of being hit with $9 million in punitive damages from its drug Vioxx, Merck is now facing lawsuits from its osteoporosis drug Fosamax. Fosamax is a defective product because it can cause osteonecrosis of the jaw, or a rotting of the jaw bone. The suit in question was filed in Ft. Myers, Florida and seeks class action status. The lawsuit alleges that Merck concealed and continues to hide Fosamax’s potentially dangerous side effects from patients and doctors.